Correlation Between Litigation Capital and Viridian Therapeutics

Can any of the company-specific risk be diversified away by investing in both Litigation Capital and Viridian Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Litigation Capital and Viridian Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Litigation Capital Management and Viridian Therapeutics, you can compare the effects of market volatilities on Litigation Capital and Viridian Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Litigation Capital with a short position of Viridian Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Litigation Capital and Viridian Therapeutics.

Diversification Opportunities for Litigation Capital and Viridian Therapeutics

0.06

Correlation Coefficient

Litigation Capital  Viridian Therapeutics

Significant diversification

The 3 months correlation between Litigation and Viridian is 0.06. Overlapping area represents the amount of risk that can be diversified away by holding Litigation Capital Management and Viridian Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Viridian Therapeutics and Litigation Capital is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Litigation Capital Management are associated (or correlated) with Viridian Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Viridian Therapeutics has no effect on the direction of Litigation Capital i.e., Litigation Capital and Viridian Therapeutics go up and down completely randomly.

Pair Corralation between Litigation Capital and Viridian Therapeutics

Assuming the 90 days trading horizon Litigation Capital Management is expected to under-perform the Viridian Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Litigation Capital Management is 2.33 times less risky than Viridian Therapeutics. The stock trades about -0.02 of its potential returns per unit of risk. The Viridian Therapeutics is currently generating about 0.08 of returns per unit of risk over similar time horizon. If you would invest  1,308  in Viridian Therapeutics on September 29, 2024 and sell it today you would earn a total of  610.00  from holding Viridian Therapeutics or generate 46.64% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	98.45%
Values	Daily Returns

Litigation Capital Management  vs.  Viridian Therapeutics

Litigation Capital

Risk-Adjusted Performance

0 of 100

Weak

Over the last 90 days Litigation Capital Management has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound technical and fundamental indicators, Litigation Capital is not utilizing all of its potentials. The newest stock price tumult, may contribute to shorter-term losses for the shareholders.

Viridian Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Viridian Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest uncertain performance, the Stock's basic indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.

Pair Trading with Litigation Capital and Viridian Therapeutics

The main advantage of trading using opposite Litigation Capital and Viridian Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Litigation Capital position performs unexpectedly, Viridian Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Viridian Therapeutics will offset losses from the drop in Viridian Therapeutics' long position.

The idea behind Litigation Capital Management and Viridian Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.